Fourth-Quarter and Full-Year 2019 Orphan and Rheumatology Segment Results

KRYSTEXXA: Improving the Patient Experience through a Shorter-Infusion Trial HORIZON Current state KRYSTEXXA infusion duration currently 2+ hours Opportunity Open-label trial evaluating the impact of administering KRYSTEXXA over a significantly shorter infusion duration Potential to meaningfully improve the experience and convenience for patients, physicians and sites of care 31

View entire presentation